Skip to main content
SpringerLink
Log in
Book cover

Thrombin pp 189–203Cite as

Anti-thrombotic Therapy in Cancer Patients

  • Chapter
  • First Online:

  • 566 Accesses

Abstract

A complex relationship exists between the coagulation system and tumour cells, with common mechanisms linking haemostasis and malignancy. Venous thromboembolism (VTE) is the second most common cause of death in cancer patients and it is estimated that about 1 in 7 patients die of avoidable pulmonary embolism (PE), rather than the cancer itself. Treating a patient with cancer requires a multidisciplinary approach, whether the intention is to cure or to palliate; life expectancy may be improved in certain patients by aggressive intervention, but if a limited life span is expected, preserving quality of life becomes paramount. Cancer is an independent risk factor for VTE, but cancer patients are also at higher risk of bleeding complications and recurrence.

Exciting data from prospective randomised clinical trials in cancer patients have now established that low molecular weight heparins (LMWHs) are the agents of choice both in the primary prevention of venous thromboembolic disease in cancer patients undergoing surgical intervention and in the treatment and long-term secondary prevention of recurrent VTE in cancer patients who develop a thrombosis. These agents can be given safely without need, in general, for routine laboratory monitoring in cancer patients.

Anti-thrombotic drugs, and in particular LMWHs, have recently been demonstrated to have potential anti-tumour effects. The survival advantage associated with LMWH usage may be due to a combination of (1) prevention of fatal thromboembolic disease; (2) interference with the coagulation proteases that influence tumour phenotype and (3) a potential direct anti-tumour cell effect of heparin itself.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Agnelli, G., et al. 2006. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann. Surg. 243:89–95

    Article  PubMed  Google Scholar 

  • Allan, A., et al. 1983. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br. J. Surg. 70:172–174

    Article  PubMed  CAS  Google Scholar 

  • Anonymous 1975. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 2:45–51

    Google Scholar 

  • Anonymous 1997. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br. J. Surg. 84:1099–1103

    Google Scholar 

  • Athanasoulis, C. A., et al. 2000. Inferior vena caval filters: Review of a 26-year single-center clinical experience. Radiology 216:54–66

    PubMed  CAS  Google Scholar 

  • Baron, J. A., et al. 1998. Venous thromboembolism and cancer. Lancet 351:1077–1080

    Article  PubMed  CAS  Google Scholar 

  • Beerepoot, L. V., et al. 2004. Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett. 213:241–248

    Article  PubMed  CAS  Google Scholar 

  • Belting, M., et al. 2004. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat. Med. 10:502–509

    Article  PubMed  CAS  Google Scholar 

  • Bergqvist, D., et al. 1995. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients [see comment]. Br. J. Surg. 82:496–501

    Article  PubMed  CAS  Google Scholar 

  • Bergqvist, D., et al. 2002. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer [see comment]. N. Engl. J. Med. 346:975–980

    Article  PubMed  CAS  Google Scholar 

  • Bern, M. M., et al. 1990. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 112:423–428

    Article  CAS  Google Scholar 

  • Bona, R. D., et al. 1995. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb. Haemost. 74:1055–1058

    PubMed  CAS  Google Scholar 

  • Boraks, P., et al. 1998. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br. J. Haematol. 101:483–486

    Article  PubMed  CAS  Google Scholar 

  • Borsig, L., et al. 2001. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98:3352–3357

    Article  PubMed  CAS  Google Scholar 

  • Brill-Edwards, P., et al. 1993. Establishing a therapeutic range for heparin therapy [see comment]. Ann. Intern. Med. 119:104–109

    Article  PubMed  CAS  Google Scholar 

  • Buller, H. R., . et al. 2004. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:401S–428S

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet, P., et al. 1996. Role of tissue factor in embryonic blood vessel development. Nature 383:73–75

    Article  PubMed  CAS  Google Scholar 

  • Clagett, G. P. Reisch, J. S. 1988. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann. Surg. 208:227–240

    Article  CAS  Google Scholar 

  • Clahsen, P. C., et al. 1994. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J. Clin. Oncol. 12:1266–1271

    PubMed  CAS  Google Scholar 

  • Contrino, J., et al. 1996. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat. Med. 2:209–215

    Article  PubMed  CAS  Google Scholar 

  • Da Silva, M. S., et al. 2003. Heparin modulates integrin-mediated cellular adhesion: Specificity of interactions with alpha and beta integrin subunits. Cell Commun. Adhes. 10:59–67

    PubMed  CAS  Google Scholar 

  • Decousus, H., et al. 1998. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N. Engl. J. Med. 338:409–415

    Article  PubMed  CAS  Google Scholar 

  • Deitcher, S., et al. 2003. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: A randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. J. Thromb. Haemost. 1:Abstract number OC194

    Google Scholar 

  • Di Carlo, V., et al. 1999. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group. Thromb. Haemost. 82:30–34

    PubMed  CAS  Google Scholar 

  • Dolovich, L. R., et al. 2000. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 160:181–188

    Article  PubMed  CAS  Google Scholar 

  • Donati, M. B., et al. 1986. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res. 46:6471–6474

    PubMed  CAS  Google Scholar 

  • Edwards, R. L., et al. 1987. Abnormalities of blood coagulation tests in patients with cancer. Am. J. Clin. Pathol. 596–602

    Google Scholar 

  • Fareed, A., Nasir, H. K. P., Michael, F., Scully, J. F., Nicholas, R. L., Ajay, K. K. 2003. The low molecular weight heparins dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model. Blood 102:Abstract #2993

    Google Scholar 

  • Gallus, A. S. 1997. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb. Haemost. 78:126–132

    PubMed  CAS  Google Scholar 

  • Gallus, A. S., et al. 1976. Prevention of venous thrombosis with small, subcutaneous doses of heparin. J. Am. Med. Assoc. 235:1980–1982

    Article  CAS  Google Scholar 

  • Goldberg, P. A., et al. 1994. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: Reduction in local treatment failure [see comment]. Eur. J. Cancer 30A:1602–1606

    Article  PubMed  CAS  Google Scholar 

  • Gordon, S. G. 1992. Cancer cell procoagulants and their implications. Hematol. Oncol. Clin. North Am. 6:1359–1374

    PubMed  CAS  Google Scholar 

  • Gould, M. K., et al. 1999. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130:800–809

    Article  PubMed  CAS  Google Scholar 

  • Harrington, K. J., et al. 1997. Cancer-related thromboembolic disease in patients with solid tumours: A retrospective analysis. Ann. Oncol. 8:669–673

    Article  PubMed  CAS  Google Scholar 

  • Harrison, L., et al. 1997. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann. Intern. Med. 126:133–136

    Article  PubMed  CAS  Google Scholar 

  • Hills, N. H., et al. 1972. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. Br. Med. J. 1:131–135

    Article  PubMed  CAS  Google Scholar 

  • Hirsh, J. M. D., et al. 1998. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. [Report]. Chest 114:489S–510S

    Article  PubMed  CAS  Google Scholar 

  • Holm, T., et al. 1996. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 78:968–976

    Article  PubMed  CAS  Google Scholar 

  • Huber, O., et al. 1992. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch. Surg. 127:310–313

    Article  CAS  Google Scholar 

  • Hull, R. D., et al. 1997. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch. Intern. Med. 157:2562–2568

    Article  PubMed  CAS  Google Scholar 

  • Hutten, B. A., et al. 2000. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis [see comment]. J. Clin. Oncol. 18:3078–3083

    PubMed  CAS  Google Scholar 

  • Iorio, A. Agnelli, G. 2000. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: A meta-analysis [see comment]. Arch. Intern. Med. 160:2327–2332

    Article  PubMed  CAS  Google Scholar 

  • Kakkar, A. K. 2003. An expanding role for antithrombotic therapy in cancer patients. Cancer Treat. Rev. 29:23–26

    Article  PubMed  Google Scholar 

  • Kakkar, V. V. Murray, W. J. 1985. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study. Br. J. Surg. 72:786–791

    Article  PubMed  CAS  Google Scholar 

  • Kakkar, A. K. Williamson, R. C. 1997. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis 27:32–37

    PubMed  CAS  Google Scholar 

  • Kakkar, A. K. Williamson, R. C. 1999. Antithrombotic therapy in cancer. Br. Med. J. 318:1571–1572

    Article  CAS  Google Scholar 

  • Kakkar, V. V., et al. 1970. Deep vein thrombosis of the leg. Is there a “high risk” group? Am. J. Surg. 120:527–530

    Article  PubMed  CAS  Google Scholar 

  • Kakkar, V. V., et al. 1993. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group [see comment]. Lancet 341:259–265

    Article  PubMed  CAS  Google Scholar 

  • Kakkar, A. K., DeRuvo, N., Chinswangwatanakul, V., Tebbutt, S., Williamson, R. C. 1995a. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346:1004–1005

    Article  CAS  Google Scholar 

  • Kakkar, A. K., et al. 1995b. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg. 82:1101–1104

    Article  CAS  Google Scholar 

  • Kakkar, A. K., et al. 1998. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 28:1–6

    PubMed  CAS  Google Scholar 

  • Kakkar, A. K., et al. 1999. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br. J. Surg. 86:890–894

    Article  PubMed  CAS  Google Scholar 

  • Kakkar, A. K., et al. 2004. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22:1944–1948

    Article  PubMed  CAS  Google Scholar 

  • Kim, H. K., et al. 2004. Platelet microparticles induce angiogenesis in vitro. Br. J. Haematol. 124:376–384

    Article  PubMed  Google Scholar 

  • Klerk, C. P. W., Smorenburg, S. M., Otten, J. M. M. B., Buller, H. R., on behalf of the MALT Stusy Group 2003. Malignancy and low molecular weight heparin therapy: The MALT trial. Pathophysiol. Haemost. Thromb. 33:75

    Google Scholar 

  • Lebeau, B., et al. 1994. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 74:38–45

    Article  PubMed  CAS  Google Scholar 

  • Lee, A. Y. 2002. Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat. Rev. 28:137–140

    Article  PubMed  CAS  Google Scholar 

  • Lee, A. Y., et al. 2003. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer [see comment]. N. Engl. J. Med. 349:146–153

    Article  PubMed  CAS  Google Scholar 

  • Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., et al. 2005. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of outpatients with cancer and venous thromboembolism. J. Clin. Oncol. 23:1–7

    Google Scholar 

  • Leizorovicz, A., et al. 1994. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br. Med. J. 309:299–304

    Article  CAS  Google Scholar 

  • Lensing, A. W., et al. 1995. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch. Intern. Med. 155:601–607

    Article  PubMed  CAS  Google Scholar 

  • Leonardi, M., et al. 2007. A systematic review of deep venous thrombosis prophylaxis in cancer patients: Implications for improving quality. Ann. Surg. Oncol. 14:929–936

    Article  PubMed  Google Scholar 

  • Letai, A. Kuter, D. J. 1999. Cancer, coagulation, and anticoagulation. Oncologist 4:443–449

    PubMed  CAS  Google Scholar 

  • Levine, M., et al. 1988. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 318:404–407

    Article  PubMed  CAS  Google Scholar 

  • Levine, M., et al. 1994. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886–889

    Article  PubMed  CAS  Google Scholar 

  • Levine, M. N., et al. 2003. From Trousseau to targeted therapy: New insights and innovations in thrombosis and cancer [Review] [79 refs]. J. Thromb. Haemost. 1:1456–1463

    Article  PubMed  CAS  Google Scholar 

  • Millward, S. F., et al. 1994. LGM (Vena Tech) vena caval filter: Experience at a single institution. J. Vasc. Interv. Radiol. 5:351–356

    Article  PubMed  CAS  Google Scholar 

  • Mohle, R., et al. 1997. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94:663–668

    Article  PubMed  CAS  Google Scholar 

  • Monreal, M., et al. 1994. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost. 71:7–11

    PubMed  CAS  Google Scholar 

  • Monreal, M., et al. 1996. Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb. Haemost. 75:251–253

    PubMed  CAS  Google Scholar 

  • Muir, J. M., et al. 1997. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236–3242

    PubMed  CAS  Google Scholar 

  • Ott, I., et al. 1998. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J. Cell Biol. 140:1241–1253

    Article  PubMed  CAS  Google Scholar 

  • Petralia, P. Kakkar, A. K. 2004. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur. J. Med. Res. 9:119–124

    PubMed  CAS  Google Scholar 

  • Petralia, G. A., Lemoine, N. R., Kakkar, A. K. 2005. Mechanisms of disease: The impact of antithrombotic therapy in cancer patients. Nat. Clin. Pract. Oncol. 2:356–363

    Article  PubMed  CAS  Google Scholar 

  • Poon, R. T., et al. 2001. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19:1207–1225

    PubMed  CAS  Google Scholar 

  • Poon, R. T. P., et al. 2003. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin. Cancer Res. 9:5339–5345

    PubMed  CAS  Google Scholar 

  • Prandoni, P., Piccioli, A. 1997. Venous thromboembolism and cancer: A two-way clinical association. Front. Biosci. 2:e12–e20

    PubMed  CAS  Google Scholar 

  • Prandoni, P. 2002. Cancer and thromboembolic disease: How important is the risk of thrombosis? [Review] [18 refs]. Cancer Treat. Rev. 28:133–136

    Article  PubMed  Google Scholar 

  • Prandoni, P., et al. 2002. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488

    Article  PubMed  CAS  Google Scholar 

  • Rahr, H. B. Sorensen, J. V. 1992. Venous thromboembolism and cancer. Blood Coagul. Fibrinolysis 3:451–460

    PubMed  CAS  Google Scholar 

  • Rem, J., et al. 1975. Subcutaneous small heparin doses for the prevention of thrombosis in general surgery and urology. Schweiz. Med. Wochenschr. Journal Suisse de Medecine. 105:827–835

    PubMed  CAS  Google Scholar 

  • Rickles, F. R. Edwards, R. L. 1983. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62:14–31

    PubMed  CAS  Google Scholar 

  • Rickles, F. R., et al. 1995. Tissue factor expression in human leukocytes and tumor cells. Thromb. Haemost. 391–395

    Google Scholar 

  • Rickles, F. R., et al. 2001. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: Tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int. J. Hematol. 145–150

    Google Scholar 

  • Rosenberg, I. L., et al. 1975. Letter: Prophylaxis of postoperative deep vein thrombosis. Br. Med. J. 3:228

    Article  PubMed  CAS  Google Scholar 

  • SackGH, L. J. Bell, W. 1977. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathologic, and therapeutic features. Medicine (Baltimore) 56:1–37

    Google Scholar 

  • Saphner, T., et al. 1991. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 9:286–294

    PubMed  CAS  Google Scholar 

  • Shaughnessy, S. G., et al. 1995. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368–1373

    PubMed  CAS  Google Scholar 

  • Shen, V. S. Pollak, E. W. 1980. Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South. Med. J. 73:841–843

    Article  PubMed  CAS  Google Scholar 

  • Shweiki, D., et al. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 843–845

    Google Scholar 

  • Siragusa, S., et al. 1996. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis [see comment]. Am. J. Med. 100:269–277

    Article  PubMed  CAS  Google Scholar 

  • Smorenburg, S. M. Van Noorden, C. J. 2001. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 53:93–105

    PubMed  CAS  Google Scholar 

  • Sorensen, H. T., et al. 1998. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N. Engl. J. Med. 338:1169–1173

    Article  PubMed  CAS  Google Scholar 

  • Sue-Ling, H. M., et al. 1986. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1:1173–1176

    Article  PubMed  CAS  Google Scholar 

  • Svendsen, E. Karwinski, B. 1989. Prevalence of pulmonary embolism at necropsy in patients with cancer. J. Clin. Pathol. 42:805–809

    Article  PubMed  CAS  Google Scholar 

  • Tallman, M. S. Kwaan, H. C. 1992. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543–553

    PubMed  CAS  Google Scholar 

  • Taniguchi, T., et al. 1998. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 58:4461–4467

    PubMed  CAS  Google Scholar 

  • The_Multicenter_Trial_Committee 1984. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. J. Am. Med. Assoc. 251:2960–2966

    Google Scholar 

  • Trousseau, A. 1872. Plegmasia Alba dolens. In Lectures on clinical medicine (delivered at the Hotel-Diue, Paris, France). The New Syndeham SocietyLondon:

    Google Scholar 

  • Virchow, R. 1856. Collected Articles on Scientific Medicine. (Gesammalte abhandlungen zurwissenschaftlichen medtzin).MedingerSohn & CoFrankfurt: pp. 219–732.

    Google Scholar 

  • Vlodavsky, I., et al. 1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5:793–802

    Article  PubMed  CAS  Google Scholar 

  • Walsh, J. J., et al. 1974. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J. Obstet. Gynaecol. Br. Commonw. 81:311–316

    Article  PubMed  CAS  Google Scholar 

  • Wang, X., et al. 2004. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int. J. Cancer. 112:994–1002

    Article  PubMed  CAS  Google Scholar 

  • Warkentin, T. E., et al. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin [see comment]. N. Engl. J. Med. 332:1330–1335

    Article  PubMed  CAS  Google Scholar 

  • Wojtukiewicz, M. Z., et al. 2001. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb. Haemost. 86:1416–1420

    PubMed  CAS  Google Scholar 

  • Wolff, R. A. 2003. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat. Rev. 29:7–9

    Article  PubMed  Google Scholar 

  • Yoshitomi, Y., et al. 2004. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 207:165–174

    Article  PubMed  CAS  Google Scholar 

  • Zacharski, L. R., et al. 1984. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53:2046–2052

    Article  PubMed  CAS  Google Scholar 

  • Zhang, Y., et al. 1994. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94:1320–1327

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thrombosis Research Institute, Emmanuel Kaye Building,Manresa Road, London, SW3 6LR, UK

    Gloria A. Petralia* & Ajay K. Kakkar

Authors
  1. Gloria A. Petralia*
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay K. Kakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gloria A. Petralia* .

Editor information

Editors and Affiliations

  1. Medical School, University of Patras, Patras, Greece

    Michael E. Maragoudakis  & Nikos E. Tsopanoglou  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Petralia*, G.A., Kakkar, A.K. (2009). Anti-thrombotic Therapy in Cancer Patients. In: Maragoudakis, M., Tsopanoglou, N. (eds) Thrombin. Springer, New York, NY. https://doi.org/10.1007/978-0-387-09637-7_11

Download citation

Publish with us

Policies and ethics

Search

Navigation